Biomerica Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Biomerica şirketinin kazançları yıllık ortalama -14.1% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 13.1% oranında artan oldu. Gelirler yıllık ortalama 2.9% oranında artan oldu.

Anahtar bilgiler

-14.1%

Kazanç büyüme oranı

-4.4%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	8.9%
Gelir büyüme oranı	2.9%
Özkaynak getirisi	-115.3%
Net Marj	-111.9%
Son Kazanç Güncellemesi	31 Aug 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Jul 14

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Dec 03

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

Dec 02

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Sep 15

Biomerica (BMRA) Investor Presentation - Slideshow

Jun 14

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Jun 13

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Apr 04

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

Mar 08

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Feb 10

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Jan 15

Biomerica soars as its COVID-19 antigen test wins European nod

Jan 12

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

Dec 20

Biomerica clinical trial for IBS nears enrollment completion

Dec 09

How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

Nov 23

Gelir ve Gider Dağılımı

Biomerica nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:BMRA Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Aug 24	6	-6	6	1
31 May 24	5	-6	5	1
29 Feb 24	5	-6	5	2
30 Nov 23	6	-6	5	2
31 Aug 23	5	-6	6	2
31 May 23	5	-7	6	2
28 Feb 23	10	-7	6	2
30 Nov 22	16	-6	6	2
31 Aug 22	19	-5	6	2
31 May 22	19	-5	6	2
28 Feb 22	15	-4	5	2
30 Nov 21	11	-7	5	2
31 Aug 21	7	-7	5	2
31 May 21	7	-7	6	2
28 Feb 21	9	-6	5	3
30 Nov 20	6	-5	4	2
31 Aug 20	7	-4	3	2
31 May 20	7	-2	2	2
29 Feb 20	5	-3	2	2
30 Nov 19	5	-2	2	2
31 Aug 19	5	-2	2	2
31 May 19	5	-2	2	2
28 Feb 19	5	-2	2	2
30 Nov 18	5	-2	2	2
31 Aug 18	5	-2	2	2
31 May 18	6	-1	2	1
28 Feb 18	6	-1	2	1
30 Nov 17	6	-1	2	1
31 Aug 17	6	-1	2	1
31 May 17	6	-1	2	1
28 Feb 17	6	-2	2	1
30 Nov 16	6	-2	2	1
31 Aug 16	5	-1	2	1
31 May 16	5	-1	2	1
29 Feb 16	5	0	2	1
30 Nov 15	5	0	1	1
31 Aug 15	5	0	1	1
31 May 15	5	0	1	1
28 Feb 15	5	0	2	1
30 Nov 14	5	0	2	0
31 Aug 14	5	0	2	0
31 May 14	5	0	2	0
28 Feb 14	5	0	1	0
30 Nov 13	5	0	1	0

Kaliteli Kazançlar: BMRA şu anda kârlı değil.

Büyüyen Kar Marjı: BMRA şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BMRA kârlı değildir ve zararlar son 5 yılda yılda 14.1% oranında artmıştır.

Büyüme Hızlandırma: BMRA 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BMRA kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 12.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BMRA hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -115.26% ) sahiptir.

Biomerica Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2025 earnings released: US$0.078 loss per share (vs US$0.067 loss in 1Q 2024)

Full year 2024 earnings released: US$0.35 loss per share (vs US$0.50 loss in FY 2023)

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Recent updates

Biomerica, Inc. Announces Direct-To-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain

First quarter 2025 earnings released: US$0.078 loss per share (vs US$0.067 loss in 1Q 2024)

Biomerica, Inc., Annual General Meeting, Dec 13, 2024

New major risk - Financial position

Full year 2024 earnings released: US$0.35 loss per share (vs US$0.50 loss in FY 2023)

Biomerica, Inc. Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers

Biomerica, Inc. Announces Infoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

Biomerica, Inc. has filed a Follow-on Equity Offering in the amount of $5.5 million.

Biomerica Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

Jack Kenny Joins Biomerica’S Board of Directors

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.008 loss in 3Q 2022)

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.089 loss in 2Q 2022)

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Steve Sloan to Step Down as Chief Financial Officer of Biomerica, Inc

Biomerica, Inc. Announces Board Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1Q 2022)

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Biomerica, Inc., Annual General Meeting, Dec 07, 2022

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Biomerica, Inc. Appoints Robert Carlson as Chief Commercial Officer

Full year 2022 earnings released: US$0.36 loss per share (vs US$0.62 loss in FY 2021)

Biomerica reports FY results

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2021)

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Biomerica, Inc. Expects Completion of Patient Enrollment for Its Infoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial This Week

Price target increased to US$13.00

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.23 loss in FY 2020)

Biomerica Announces Notice of Allowance for Patent on Product Used to Diagnose and Treat Depression

Biomerica, Inc. Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment

Biomerica (BMRA) Investor Presentation - Slideshow

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.088 loss in 3Q 2020)

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

New 90-day high: US$8.00

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

New 90-day high: US$7.50

Second quarter 2021 earnings released: US$0.13 loss per share

Earnings beat expectations, revenue disappoints

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Biomerica, Inc. Receives CE Mark for its New Covid-19 Rapid Antigen Test for Detection of Covid-19 Infection

Analysts lower revenue estimates to US$8.51m

Biomerica soars as its COVID-19 antigen test wins European nod

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

New 90-day low: US$5.38

Biomerica, Inc. Announces Corporate Secretary Changes

Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

Biomerica clinical trial for IBS nears enrollment completion